



DISCLAIMER

This presentation is not a prospectus nor an offer for securities in any jurisdiction nor a securities recommendation. The information in this presentation is an overview and is based on publicly available information and internally developed data and does not contain all information necessary for investment decisions. In making investment decisions in connection with any acquisition of securities, investors should rely upon their own examination of the assets and consult their own legal, business and/or financial advisors and should not be relied on in connection with a decision to purchase or sell any securities.

The information contained in this presentation has been prepared in good faith by HRL Holdings Limited ("HRL") however, no representation nor warranty expressed or implied is made as to the accuracy, correctness, completeness or adequacy of any statements, estimates, opinions or other information contained in this presentation.

Investment in HRL is subject to investment risk, including possible loss of income and capital invested. The occurrence of events in the future are subject to risks, uncertainties and other factors that may impact HRL's actual results, performance or achievements to differ from those referred to in this presentation. Neither HRL, nor any other member company of the HRL Group, nor any officer or employee guarantees any particular rate of return or performance, nor do they guarantee the repayment of capital. Further, they do not give any assurance or guarantee that the occurrence of the events referred to in this presentation will actually occur as contemplated.

The presentation may contain forward-looking statements regarding the potential of the Company's revenues, projects, interests and the development potential of the Company's business. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Given these risks, readers are cautioned not to rely on forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risk associated with product sales, development and manufacture, risks inherent in the business, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.





SOCIAL RESPONSIBILITY



Reduced disposable laboratory plastics by 40% at Analytica



25% reduction in total reportable injuries in second half









WHO WE ARE











WHAT WE DO







LABORATORY SERVICES









BRANCH NETWORK






WHO BUYS OUR TESTING















WHY THEY BUY IT









MEGATRENDS DRIVING DEMAND



Rising Asian demand for clean and green Australasian food



Rising consumer demand for authentic and traceable food and beverages



Private & public sector focus on environmental stewardship and social licence



Increasing regulation and the need for demonstrable compliance



Focus on personal / worker health and well-being



OUR MAJOR SHAREHOLDERS


Share holder composition:

Board and management	~19%
Institutional	~55%
Other	~26%

Substantial holder notices >5%

Viburnum Funds	21%
Perennial Value	15%
Entities associated with Terry Cooney	7%










FY2019:REBUILDING EARNINGS BASE



^{*}Average of Canaccord Colts and Morgans Financial forecast

FINANCIAL HIGHLIGHTS

ŀ	4	F	9	L

	FY2019 \$000's	FY2018 \$000's	INCREASE \$000's
Revenues	30,755	27,307	3,448
Underlying EBITDA ¹	4,451	5,775	(1,324)
Underlying NPAT	1,534	2,874	(1,340)
Operating cash flows generated ²	2,747	4,567	(1,820)
Working capital ³	2,025	3,229	(1,204)
Net cash/(borrowings) ⁴	(3,567)	4,278	(7,845)
Statutory loss after tax ⁵	(7,127)	(1,504)	(5,623)

- 1. Underlying EBITDA, EBIT and NPAT reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Group, in accordance with AICD/Finsia principles of recording underlying earnings. Underlying profit measures have not been audited. Refer to Appendix A for further details of non-underlying items.
- 2. Excludes cash outflows associated with vendor earnout costs.
- 3. Working capital is defined as net current assets, excluding an interest only loan drawn to \$1,911,741 which has no expiry but it subject to annual review by Westpac.
- 4. HRL has additional undrawn facilities at 30 June 2019 of \$1,918,727.
- 5. Statutory loss includes non-operating items as detailed in Appendix A



SEGMENT PERFORMANCE – FY2019


	TRADING DIVISIONS			CORPORATE	CONSOLIDATED		
	HAZMAT	GEOTECH	FOOD/ENVIRO	SOFTWARE	TOTAL		
	\$000's	\$000's	LABORATORY \$000's	\$000's	\$000's	\$000'S	\$000's
Revenues	7,762	8,028	14,204	735	30,729	-	30,729
Underlying EBITDA (\$)	736	707	4,595	246	6,283	(1,833)	4,451
Underlying EBITDA (%)	9%	9%	32%	33%	20%	-	14%
Operating depreciation and amortisation	(435)	(207)	(1,497)	(45)	(2,184)	(10)	(2,194)
Net interest expense	(48)	(17)	-	-	(66)	(70)	(136)
Underlying profit before tax	253	483	3,098	200	4,034	(1,912)	2,121
Operating income tax	(69)	(133)	(867)	(55)	(1,125)	538	(587)
Underlying profit after tax	183	350	2,230	145	2,909	(1,375)	1,534
Non-operating adjustments							
Food Lab Pacific establishment expenses	-	-	(22)	-	(22)	-	(22)
Earn-out expenses/adjustments	-	-	(5,257)	188	(5,070)	-	(5,070)
Amortisation of intangible assets arising from acquisitions	(102)	(806)	(1,812)	(882)	(3,602)	-	(3,602)
Impairment of goodwill	(661)	-	-	-	(661)	-	(661)
One-off restructure expenses	(215)	(133)	-	-	(348)	-	(348)
Lapsed performance shares	-	-	-	-	-	(62)	(62)
Share of profits - equity accounted investments	-	-	3	-	3	-	3
Non-operating income tax	88	258	513	243	(1,102)	-	(1,102)
Statutory profit after income tax	(707)	(331)	(4,344)	(307)	(5,690)	(1,437)	(7,127)



H2FY19: RECOVERY UNDERWAY

- NZ government moved quickly to change the property contamination thresholds in H1FY19
- Changes resulted in less property testing throughout FY19 impacting sampling and laboratory volumes (circa \$2.5M EBITDA impact)
- HRL restructured cost base, and focussed growth back into hazmat, food and environmental testing
- Strategy back on track for recovery into FY2020





^{*} FY2018 figures are on a pro-forma basis including the full 12 month trading results for Analytica.



H2FY19: OPERATIONAL HIGHLIGHTS

Restructured NZ Hazmat division, completed in February. Subsequent months trading have each produced EBITDA >20% per month

Precise laboratories transferred across to Analytica and fully integrated

\$940k

Annualised cost savings achieved through strategic restructuring

ANALYTICA

developing
Al capability for image
recognition

AI

New laboratory tests launched including:

Glyphosate testing

Beta-casein genotyping

Oxygen isotope trace

CAIQTEST PACIFIC JV

continues to work with Chinese authorities to expand testing services.

FOODLAB JV has commenced method development with 4 staff



ANALYTICA REVENUE GROWTH FY19 v PCP



Dairy +16%



Environmental +93%



Honey +14%



Authenticity & Trace +51%



Drugs of abuse (methamphetamine) -48%




HAZMAT DIVISION

	Performance commentary	Actions taken to improve
70	NZ property contamination (methamphetamine) revenues -77%	Restructured NZ to cut overhead costs and transfer laboratory operations to Analytica
a	Asbestos revenue -20% in Australia with completion of ACT loose-fill projects	Closed ACT branch
	Environmental laboratory in Australia being established under guidance of Analytica management	Continued to drive organic growth in scalable laboratory services to diversify away from labour centric projects



OUR FY2019 DELIVERABLES



Future Developments



OUTLOOK FOR FY2020

Return to FY2018 level of profitability, replacing the meth testing decline in demand

Integrate business unit support services for HR, finance and IT infrastructure Secure and build out new laboratory facilities for Analytica NZ (main site Hamilton) to facilitate long term growth and improve workflow efficiencies

Continue to drive organic service development with a focus on scalable laboratory-based services

Grow earnings from data management / software division

Support HRL's JV investments to realise strategic potential

CONTACTS AND MORE INFORMATION

Steven Dabelstein | CEO +61 405 770 166 steven.dabelstein@hrlholdings.com

Michael Harvey | CFO +61 409 334 366 michael.harvey@hrlholdings.com

www.hrlholdings.com





APPENDIX A

DETAILS ON NON-OPERATING PROFIT ADJUSTMENTS

ADJUSTMENT	DESCRIPTION
Food Lab establishment expenses	Legal and other expenses related to the formation of the Food Lab Pacific joint venture with MilkTest NZ.
Earn-out expenses/adjustments	The Analytica vendors achieved the full earn-out profit target resulting in the full earn-out payment of NZ\$11,000,000. Payment of the earn-out consideration is contingent on ongoing service of certain key staff and is recognized progressively over the service period. The expense recognized in FY2019 was NZ\$5,500,000 or AU\$5,257,121.
	OCTFOLIO did not exceed the minimum profit target to achieve the first stage earn-out payment and consequently the previously recognised provision of \$187,500 was reversed in FY2019.
Amortisation of intangible assets arising from acquisitions	The excess purchase price over the value of both the tangible assets and goodwill acquired during the acquisitions of Analytica, AAC Environmental, RJL & Associates, Morrison Geotechnic and OCTFOLIO has been allocated against specific identifiable intangible assets. These intangible assets are being amortised over a 2 – 5 year period.
Impairment of goodwill	With the conclusion of the "Mr Fluffy" asbestos program in the ACT and surrounding areas, and limited other opportunities in the region, OCTIEF closed its ACT branch. Previously acquired goodwill relating to this branch has been written down to nil.
One-off restructure expenses	One-off employee redundancies, premises closures and relocations costs relating to the: Transfer of Precise laboratories to Analytica Relocation and restructure of the Morrison Gold Coast facility Closure of the OCTEIF ACT branch
Equity accounted share of profits	Both Food Lab Pacific Limited and CAIQTest (Pacific) Limited remain at an early phase of development and accreditation.
Lapsed performance shares	In August 2016 HRL introduced a long term incentive plan for key management. The performance conditions of these instruments were not met and the performance shares have now lapsed in full. The value of these performance shares was recognized as an expense in the income statement over the vesting period. HRL will be introducing a revised long term incentive plan in FY2020. The plan is designed to provide a strong link to shareholder value and long term sustainable growth. The LTI Plan will contain four performance hurdles of TSR, EPS, EBITDA and ROCE which will ensure active capital management and
	will drive sustainable financial performance over the longer term as well as ensure a fair outcome for shareholders and management. Further details of the FY2020 LTI Plan are included in the Annual Report.